Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 979993269
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2008.12.19, US 139536 P
2009.01.14, US 144731 P
2009.01.15, US 205145 P
A. ALOMAR ET AL: "Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head", BRITISH JOURNAL OF DERMATOLOGY, vol. 157, no. 1, 1 July 2007 (2007-07-01), pages 133-141, XP55036836, ISSN: 0007-0963, DOI: 10.1111/j.1365-2133.2007.07942.x (B1)
CHEN ET AL.: 'Short-Course Therapy with Imiquimod 5% Cream for Solar Keratoses: A Randomized Controlled Trial.' AUSTRALASIAN JOURNAL OF DERMATOLOGY vol. 44, 2003, pages 250 - 255, XP008143820 (B1)
HANKE C W ET AL: "Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 62, no. 4, 1 April 2010 (2010-04-01), pages 573-581, XP026942785, ISSN: 0190-9622, DOI: 10.1016/J.JAAD.2009.06.020 [retrieved on 2010-02-04] (B1)
JORIZZO ET AL.: 'Vehicle-Controlled, Double-Blind, Randomized Study of Imiquimod 5% Cream Applied 3 Days Per Week in One or Two Courses of Treatment for Actinic Keratoses on the Head.' JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY vol. 57, no. 2, August 2007, pages 265 - 268, XP022140815 (B1)
WO-A1-2008/098232 (B1)
K. GEBAUER ET AL: "Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial", BRITISH JOURNAL OF DERMATOLOGY, vol. 161, no. 4, 1 October 2009 (2009-10-01), pages 897-903, XP55036934, ISSN: 0007-0963, DOI: 10.1111/j.1365-2133.2009.09260.x (B1)
KORMAN ET AL.: 'Dosing With 5% Imiquimod Cream 3 Times per Week for the Treatment of Actinic Keratosis.' ARCH DERMATOL. vol. 141, 2005, pages 467 - 473, XP008140915 (B1)
SWANSON N ET AL: "Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 62, no. 4, 1 April 2010 (2010-04-01), pages 582-590, XP027031604, ISSN: 0190-9622 [retrieved on 2010-02-04] (B1)
US-A1- 2008 280 943 (B1)
JOSEPH L JORIZZO: "Current and Novel Treatment Options for Actinic Keratosis", JOURNAL OF CUTANEOUS MEDICINE AND SURGERY ; INCORPORATING MEDICAL AND SURGICAL DERMATOLOGY, SPRINGER-VERLAG, NE, vol. 8, no. 3, 1 December 2004 (2004-12-01), pages 13-21, XP019368360, ISSN: 1615-7109 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP2378876)
|
Innkommende, AR309797000
Korrespondanse (Hovedbrev inn)
|
Utgående
EP defect letter
|
Innkommende, AR306555158
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 16. avg. år (EP) | 2024.12.19 | 6760 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 15. avg. år (EP) | 2023.12.19 | 4850 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 14. avg. år (EP) | 2022.12.20 | 4500 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 13. avg. år (EP) | 2021.12.27 | 4200 | ANAQUA ANAQUA | Betalt og godkjent |
Årsavgift 12. avg. år (EP) | 2020.11.26 | 3850 | MASTER DATA CENTER INC | Betalt og godkjent |
Årsavgift 11. avg. år (EP) | 2019.11.25 | 3500 | MASTER DATA INC | Betalt og godkjent |
Forsinkelsesavgift patent | 2019.04.25 | 700 | MASTER DATA INC | Betalt og godkjent |
Årsavgift 10. avg. år (EP) | 2019.04.25 | 3200 | MASTER DATA INC | Betalt og godkjent |
31903281 expand_more expand_less | 2019.03.05 | 5500 | BRYN AARFLOT AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|